WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view.

J Thorac Dis · 2021 · PMC8182552 · PMID 34164217

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results of study performed in NSCLC patients which compared motexan gadolinium (MGd) used with WBRT and WBRT alone showed a trend toward improved time to neurological progression and time to neurocognitive destroying with use of MGd.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.